Abstract

With the beneficial goal of generating new applications from known drugs, the chemistry and biology groups of Dr. Martin J. Lear and Prof. Yao Shao Qin have teamed up to develop an anti-cancer agent out of the FDA-approved anti-obesity drug called Orlistat (also known as tetrahydrolipstatin, THL). Their strategy combines the techniques of total synthesis and chemical proteomics to generate THL-probes capable of trapping off-target proteins.